Get up to date with the latest EHA-EU guideline for Mantle Cell Lymphoma (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) with Prof Mats Jerkeman (Lund University, Sweden).  

In this episode, he explains how biological risk factors, particularly TP53 mutations and proliferation rate, inform patient stratification. He reviews evolving treatment sequencing, including  the expanding role of  BTK inhibitors (such as ibrutinib) in first-line regimens. 

He further discusses the management relapsed/refractory MCL, where BTK inhibitors and CAR T-cell therapy  have largely supplanted but not fully replaced allogeneic transplantation. 

Throughout the conversation, Prof Jerkeman emphasizes the dynamic evolution of MCL treatment and the need for ongoing guideline updates as new evidence emerges. 

Link to the guideline: (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) 

Link to Lund University:  

Mats Jerkeman - Lund University 

Home | Lund University  

Learn More

Interested in more content related to CART? We've got you covered. Check out free CART program on ⁠EHA Campus⁠.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠Provide Feedback⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠https://ehaedu.org/Campus⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠

Facebook: ⁠https://e-h-a.link/facebook⁠

LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠